Stifel Starts Spark Therapeutics (ONCE) at Buy
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Stifel initiated coverage on Spark Therapeutics (NASDAQ: ONCE) with a Buy rating and a price target of $73.00.
Shares of Spark Therapeutics closed at $57.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Upgrades Legacy Reserves (LGCY) to Hold
- FBR Capital Remains Bullish Following Select Income REIT's (SIR) 3Q Miss
- UPDATE: MKM Partners Upgrades Masco (MAS) to Buy
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!